Standard BioTools and SomaLogic to merge in all-stock deal valued over $1B

STANDARD BIOTOOLS INC.

SomaLogic shareholders get 1.11 LAB shares per SLGC share; combined ownership ~57% SLGC, ~43% LAB.
Estimated $80M annual cost synergies by 2026; pro-forma 2023 revenue >$180M.
Combined cash >$500M at close; LAB raises FY2023 revenue guidance to $100-105M.
Michael Egholm to become CEO of combined company; Jeffrey Black as CFO.
Standard BioTools and SomaLogic stockholders representing ~16% and ~1% voting power sign voting agreements.

item 1.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

STANDARD BIOTOOLS INC. entered into Agreement and Plan of Merger with SomaLogic, Inc. (effective 2023-10-04).

Action: entry
Agreement: merger
Counterparty: SomaLogic, Inc.
Effective: 2023-10-04

Exact text from the filing

On October 4, 2023, Standard BioTools Inc., a Delaware corporation (“Standard BioTools” or the “Company”), SomaLogic, Inc., a Delaware corporation (“SomaLogic”), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”)

View on SEC.gov

Browse all material agreements →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-106606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.